By enGenes Biotech…
Subscribe to Supplier
Subscribe to Supplier
Presenting solutions for continuous pDNA production at Bioprocessing Summit USA
Vienna, Austria: – Recombinant proteins and plasmid DNA specialist CDMO enGenes Biotech is returning to the annual CHI Bioprocessing Summit with further insights on groundbreaking continuous production technologies for plasmid DNA (pDNA).
Since last year, enGenes has begun attending both the European and American Bioprocessing Summits as its patented expression and purification platforms become increasingly important in progress towards more sustainable and efficient continuous production of proteins and pDNA.
Continuous pDNA manufacturing solutions
At the previous Boston summit, enGenes CEO and co-founder Dr. Jürgen Mairhofer delivered a presentation on fully end-to-end continuous production of recombinant proteins using E. coli. This time, he will show how similar technologies and concepts are helping to master the pDNA challenge.
His Day Two presentation ‘iCAP: Integrated Continuous & Automated Platform for Plasmid Production’ (Tuesday, Aug 11 at 17:10) will close out the Intensified & Continuous Bioprocessing session as part of the summit’s Intensification & Digitalization track.
iCAP – integrating bioprocess intensification with digital intelligence
Plasmid DNA underpins viral vectors, mRNA vaccines, and DNA therapeutics, yet production is limited by costly, low-yield batch processes. Dr. Mairhofer will show how the iCAP research program aims to transform the situation with a continuous, automated microbial platform integrating bioprocess intensification and digital intelligence.
The program is developing a system that combines genetically stabilized E. coli and a growth-decoupled replication system to enable stable, long-term plasmid production in bioreactor cascades.
iCAP is envisaged as a modular and scalable platform to reduce costs and environmental impact while supporting decentralized vaccine manufacturing and integrated therapeutic supply – setting a new benchmark for sustainable, next-generation plasmid DNA biomanufacturing.
Leveraging technologies
Jürgen Mairhofer will explain how continuous alkaline lysis, chromatographic purification, and real-time digital twin–based control can ensure high-throughput, low-variability recovery. He will also show how enGenes’ proprietary technology platforms, including -eXcite for continuous manufacturing of biomolecules in E. coli, -eXrase hi-tech endonuclease, and -eXffinity affinity ligands are key enablers for increased process efficiency.
enGenes is also treating the Summit as a primary networking opportunity, with Dr. Mairhofer participating in its various face to face meetings and virtual engagements via the Summit’s 1:1 platform.
Dr. Mairhofer commented: “We always welcome opportunities to talk to potential partners or collaborations. I hope anyone interested in meeting us In Boston will contact us at the event or, even better, beforehand so we can set up a meeting.”
About enGenes Biotech
enGenes Biotech GmbH (enGenes) is a contract research, development and manufacturing company that provides leading-edge technologies and production services focused on recombinant proteins in bacteria. The company’s mission is to provide cost-effective and scalable production of recombinant proteins at a fraction of the current cost, allied to a vision of developing a world-class portfolio of cutting-edge protein production technologies, relevant to a broad spectrum of application fields.
enGenes has developed advanced technologies to drive more cost-effective recombinant protein production processes, including its proprietary enGenes-eXpress™ E. coli platform that achieves outstanding yields of soluble and active recombinant protein. enGenes- eXpress™ has been successfully applied for the manufacturing of enzymes and biopharmaceutical products that failed to give economically feasible yields in a conventional expression host.
enGenes Biotech offers development and manufacturing services tailored to the needs of pharmaceutical and industrial biotech companies. The services include expression strain and vector development, fermentation process development and optimization, downstream process development, production of purified protein, technology transfer and scale-up support with technology out-licensing and co-development opportunities.
Find out more at: https://www.engenes.cc
About Bioprocessing Summit USA 2026
The Bioprocessing Summit convenes more than 1,000 international bioprocessing professionals to share practical solutions for today’s bioprocess challenges. These include including upstream and downstream processing, analytical quality, formulation and stability, cell and gene therapy production, and manufacturing.
Since foundation in 2017, the event has hugely grown in scope and now encompasses 12 conference tracks including around 300 presentations.
The 18th US Bioprocessing Summit is a four-day event opening August 10, again at the Omni Boston Hotel at the city’s Seaport district. Content is also available online with the Virtual Bioprocessing Summit platform.
Under its overall theme ‘Transforming Bioprocessing for the Digital Age’ the 2026 conference will explore how technology, data, and AI are reshaping every stage of the bioprocessing journey, including topics such as CMC for Biotherapeutic Products, Cell Therapy Analytics, Intensified & Continuous Bioprocessing, and Analytical Intelligence.
The event is organized by Cambridge Healthtech Institute (CHI) with more information available at: https://www.bioprocessingsummit.com
Resources
Click on Intensified and Continuous Bioprocessing for more on Bioprocessing Summit discussion, including enGenes contribution.
Click on iCAP Project targets world-first continuous pDNA production to learn more.
Contact enGenes to set up meeting at Bioprocessing Summit USA.
Dr. Juergen Mairhofer, CEO and co-founder, enGenes Biotech GmbH.
Related Articles
